Heart failure & cardiomyopathies
Cilostazol in Patients with Heart Failure and Preserved Ejection Fraction—The CLIP-HFpEF Trial
Primary result · Improvement in KCCQ scoreResult — go to the resultDifference 4.8 points 95% CI 2.0–7.7Authors' conclusion
Amongst patients with HFpEF, short-term treatment with cilostazol leads to improvements in health status and NT-proBNP when compared with placebo.
Study context
- Population
- Patients with heart failure with preserved ejection fraction (HFpEF)crossover
- Participants
- 23 patients
- Comparison
- Cilostazol vs placebo
- Primary endpoint
- Kansas City Cardiomyopathy Questionnaire (KCCQ-12) overall summary score
- Follow-up
- End of each treatment period
Methodological detailsplacebo-controlled, multiple crossover
- Placebo-controlled
- Multiple crossover
Primary result
Improvement in KCCQ score
Difference
4.8 points
95% CI 2.0–7.7
P = 0.003
Cilostazolvs Placebo
difference 4.8 points (95% CI 2.0–7.7); P = 0.003
As reported in the abstract
Secondary outcomes
NT-proBNP
P = 0.006
Diastolic PA pressure (exploratory, 5 with implanted pressure monitors)
- Diastolic pulmonary artery (PA) pressure (exploratory, 5 with implanted pressure monitors) — Effect linked to higher heart rates
- P < 0.001
Original publication
Cilostazol in Patients with Heart Failure and Preserved Ejection Fraction—The CLIP-HFpEF Trial. ESC Heart Fail. Published 17 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →